Six new members join the EUCOPE network
BioPharma
United Kingdom Bruxelles Capitale Stephane Martin Alexander Roussanov Laboratoire Cevidra Arnold Porter
Source: biopharmadive.com
📰 Urovant Sciences News
Page 4 - Urovant Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Urovant Sciences. Real-time updates on events, politics, business and more.
Urovant Sciences, Inc.: Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium
Source: finanznachrichten.de
Urovant Sciences, Inc.: Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the
Source: finanznachrichten.de
Egle Therapeutics SAS: Egle Therapeutics Appoints Pierre Legault as Chairman and Board Member
Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault as Chairman
Kostenloser Wertpapierhandel Eliane Piaggio Amolyt Pharma Artios Pharma Pierre Legault Institut Curie
Source: finanznachrichten.de
Truvian Sciences Appoints Top Industry Veterans to its Leadership Team as it Prepares to Commercialize its Automated Benchtop Blood Testing System
Truvian Sciences Appoints Top Industry Veterans to its Leadership Team as it Prepares to Commercialize its Automated Benchtop Blood Testing System - read this article along with other careers information, tips and advice on BioSpace
United States New Delhi Mechanical Engineering Dainippon Sumitomo Pharma Eric Zieger Dena Marrinucci
Source: biospace.com
Urovant Sciences, Inc.: Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA in Dry and Wet Overactive Bladder Populations
Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears
Source: finanznachrichten.de
CORRECTING and REPLACING Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
CORRECTING and REPLACING Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice P
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth and sixth paragraphs.The updated release reads:UROVANT SCIENCES ANNOUNCES APPOINTMENT OF SEF KURSTJENS AS EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICERUrov...
South Africa Sumitomo Pharma Alana Darden Powell James Robinson Cornelia Haag Molkenteller Allergan Inc
Source: pharmiweb.com
Urovant Sciences, Inc.: Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA's role as an effective treatment option for overactive bladder (OAB)
United States Sumitomo Dainippon Pharma Sumitovant Biopharma Maya Frutiger Alana Darden Powell Cornelia Haag Molkenteller
Source: finanznachrichten.de
Urovant Sciences, Inc.: Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma
United States Beaumont Hospital Royal Oak Sumitomo Dainippon Pharma Sumitovant Biopharma Kenneth Peters
Source: finanznachrichten.de